Photobiomodulation of gingival lesions resulting from autoimmune diseases: systematic review and meta-analysis

Objectives To evaluate the effects of photobiomodulation (PBM) in gingival lesions resulting from autoimmune diseases; to compare PBM and topical corticosteroid (CS) treatment; and to assess PBM outcome over time of follow-up. Materials and methods A comprehensive electronic search was performed in...

Full description

Saved in:
Bibliographic Details
Published in:Clinical oral investigations 2022-05, Vol.26 (5), p.3949-3964
Main Authors: de Carvalho, Milena Moraes, Hidalgo, Marco Antonio Rimachi, Scarel-Caminaga, Raquel Mantuaneli, Ribeiro Junior, Noé Vital, Sperandio, Felipe Fornias, Pigossi, Suzane Cristina, de Carli, Marina Lara
Format: Article
Language:English
Subjects:
Adrenal Cortex Hormones - therapeutic use
Autoimmune diseases
Autoimmune Diseases - drug therapy
Autoimmune Diseases - radiotherapy
Dentistry
Gingiva
Glucocorticoids - therapeutic use
Humans
Lesions
Lichen planus
Lichen Planus, Oral - drug therapy
Lichen Planus, Oral - radiotherapy
Light therapy
Medicine
Meta-analysis
Original
Original Article
Pain
Skin diseases
Steroids
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives To evaluate the effects of photobiomodulation (PBM) in gingival lesions resulting from autoimmune diseases; to compare PBM and topical corticosteroid (CS) treatment; and to assess PBM outcome over time of follow-up. Materials and methods A comprehensive electronic search was performed in four electronic databases. Treatment effects were measured through visual analog scale of pain (VAS) and clinical evolution of lesion (Thongprasom scale for oral lichen planus (OLP)). Meta-analysis was performed to compare PBM with topical corticosteroid treatment and to evaluate PBM effect over time of follow-up. Results Seventeen studies were included in this review, of which six were used for the meta-analysis. Meta-analysis results showed no significant differences between PBM and topical CS in pain reduction at baseline (MD = 0.20, 95% CI =  − 0.92, 1.32, p  = 0.72) and 60-day follow-up (MD = 0.63, 95% CI =  − 3.93, 5.19, p  = 0.79); however, VAS showed significant pain reduction when compared before and after PBM at 30-day (MD =  − 3.52, 95% CI =  − 5.40, − 1.64, p  = 0.0002) and 60-day (MD =  − 5.04, 95% CI =  − 5.86, − 4.22, p  
ISSN:1436-3771
1432-6981
1436-3771
DOI:10.1007/s00784-021-04362-0